Effectiveness of rimegepant in vestibular migraine: a prospective self-controlled cohort study
Abstract
Vestibular migraine (VM) is the second most common cause of episodic vertigo worldwide, yet effective therapeutic options remain limited. This study aimed to assess the clinical effectiveness of rimegepant in patients with VM. A total of 33 VM cases were enrolled in this multicenter, prospective self-controlled cohort study, screened from an initial pool of 106 patients. Participants were orally administered rimegepant at 75 mg every other day as a preventive therapy. Mean 4-week days of vestibular symptom or headache, along with Dizziness Handicap Inventory (DHI), Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Headache Impact Test-6 (HIT-6), Vertigo Symptom Scale–Short Form (VSS-SF), Activities-specific Balance Confidence Scale (ABC) scores, and hearing sensitivities were compared between pre-dosing and postdosing of rimegepant over a 4-week follow-up. At baseline, participants exhibited a high symptom burden, with elevated DHI, VSS-SF, GAD-7, PHQ-9, and HIT-6 scores and low ABC scores. After rimegepant treatment, there were substantial reductions in monthly vestibular symptom days and headache days (differences: vestibular symptoms, -8.48; headache, -5.88). Totally 63.6% and 70.4% of the patients experienced a 50% reduction in vestibular symptom days and headache days, respectively. Notably, these improvements were already apparent at 2 weeks, indicating early onset of efficacy. Additionally, rimegepant treatment led to significant…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 106 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.